IMRN
Immuron Limited
NASDAQ · Healthcare · Biotechnology · AU
$1.80
+62.16%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
Market Cap
$14.53M
MomentumView details →
1D Return
+62.16%
YTD Return
+122.95%
RSI (14)
76.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
Market Cap
$14.53M
RSI (14)
76.6
MomentumView details →
1D Return
+62.16%
YTD Return
+122.95%
SummaryUpdated Jun 1, 2026
Immuron Limited (NASDAQ:IMRN) is an Australian-based biopharmaceutical company founded in 1994 that specializes in developing and commercializing polyclonal antibody therapies. The company went public on NASDAQ in 2017 and operates through two main segments: Research and Development, and Hyperimmune Products. Immuron focuses on gastrointestinal health solutions, leveraging its proprietary technology platform based on bovine colostrum with hyperimmune antibodies to create both over-the-counter products and prescription drug candidates.
Similar companies
Latest newsMore news →